November 3rd 2017
A multihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor,
July 29th 2017
Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation.
July 27th 2017
Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.
July 26th 2017
Rami Komrokji, MD, shares his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.
July 25th 2017
Mohamed Kharfan-Dabaja, MD, discusses the future of PNH treatment, the various symptoms that can present in PNH, and the challenges that still remain for further improving outcomes.
July 24th 2017
Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.
July 17th 2017
Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.